LifeCodexx is now offering three options for its next-gen sequencing-based noninvasive fetal aneuploidy test, PraenaTest. The standard option includes testing for trisomies 21, 18, and 13. One option includes testing for only trisomy 21. An expanded option includes testing for trisomies 21, 18, and 13, as well as the determination of fetal gonosomal aneuploidy for singleton pregnancies, such as Turner, Triple X, Klinefelter, and XYY syndromes. In addition, starting in 2015, patients will be able to be refunded by their statutory health insurances for a trial period.